Management of Diltiazem in Thyrotoxicosis

Recommendation

• The American College of Cardiology recommends that diltiazem should be discontinued in a patient with thyrotoxicosis who has a normal heart rate and is experiencing tiredness, as it is not indicated in this clinical scenario and may be contributing to the fatigue 1, 2

Rationale for Discontinuation

• Beta blockers are the first-line agents recommended for controlling cardiovascular symptoms in thyrotoxicosis, with calcium channel blockers like diltiazem only recommended when beta blockers cannot be used, according to the American College of Cardiology and European Heart Journal 1, 2
• Diltiazem is specifically indicated for controlling ventricular rate in patients with thyrotoxicosis who have tachycardia or atrial fibrillation, not for patients with normal heart rates, as stated by the American College of Cardiology 3, 2

Management Algorithm

• The American College of Cardiology suggests assessing cardiac status, and if heart rate is normal, diltiazem provides no benefit for rate control 1, 2
• Diltiazem should only be continued if there is documented atrial fibrillation or tachycardia despite the current normal heart rate, according to the American College of Cardiology 3
• The European Heart Journal recommends evaluating thyroid status and focusing on achieving euthyroid state through appropriate anti-thyroid therapy 2, 4

Evidence Analysis

• Guidelines from the American College of Cardiology/American Heart Association/European Society of Cardiology consistently recommend calcium channel antagonists like diltiazem only when beta blockers cannot be used and only for controlling rapid ventricular response 1, 5, 2

Important Caveats

• If diltiazem is discontinued, monitor the patient closely for development of tachycardia or atrial fibrillation as thyrotoxicosis progresses, as advised by the American College of Cardiology and European Heart Journal 3, 2
• The primary treatment goal should be achieving a euthyroid state, which will often resolve cardiovascular symptoms without the need for rate-controlling medications, according to the European Heart Journal 2, 4
• If rate control becomes necessary later due to development of tachycardia, beta blockers should be considered first-line unless contraindicated, as recommended by the American College of Cardiology 1, 3, 2